Tissue Engineering Cell Therapy for Knees
Both autologus (your own) and placental derived cell therapy can produce fantastic results for osteoarthritis of the knee. Each has its own unique set of advantages. Nothing is better then self and autologus cells are just that. They have a “eureka” day usually within 21 days of grafting and in our hands seem to have a faster onset of action then placental derived. That means that relief can come on quicker in the majority of cases when autologus cells are used. There are draws back however: they have to be harvested and also require a PRP (platelet rich plasma) booster at one month in order to get full impact. Placental cells appear to be a bit slower to work but they also seem to keep working a bit longer than autologus (peek healing is quicker with autologus). On the other hand no harvest is required, the grafting procedure is simple, and a 30 day booster is not required. We have had great results with each. In our hands 74% of patients had more than 80% relief after 6 months. We have success indicators for other conditions as well. For difficult cases like chronic low back pain 67% reported at least 80% relief, and 72% reported at least 50% relief. For CRPS/RSD, Peripheral Neuropathy, and Peripheral Vascular Disease (PAD) 43% reported at least 90% relief and 86% reported at least 50% relief. Finally, with hips, ankles and shoulders 50% achieved 50% relief or more . Tissue engineering cell therapy for knee osteoarthritis is a great option for those who want to avoid arthroscopy or knee joint replacement. Learn more at piedmontpmr.com.